Our blog

Explore the latest blogs from Lhasa

Discover how Vitic can assist with providing expert toxicity data for the ICH M7 guidelines on mutagenic impurities for an efficient workflow.

Driving efficient early-stage ICH M7 classification through reliable mutagenic and carcinogenic data

In this latest blog, we will define the difference between certainty and uncertainty in the ICH M7 guideline for mutagenic impurities. Delving …

Applying ICH S1B(R1) in 5 steps: Carcinogenicity assessment made simple with Kaptis

Carcinogenicity assessment is a critical step in drug development. Teams must balance regulatory compliance, development timelines, and ethical testing, often with incomplete …

ICH M7 control option 4: How to confidently demonstrate control of mutagenic impurities in API synthesis (without analytical testing)

If you’re currently relying solely on analytical testing to check for mutagenic impurities in your active pharmaceutical ingredient (API), there is a …

EUROTOX 2025: Highlights from Athens

Insights on ICH S1B(R1), genotoxicity and best practices in toxicology. The 59th Congress of the European Societies of Toxicology (EUROTOX) brought the …

Ready to discover the power of in silico chemical structure search using Vitic? Here's everything you need to know about toxicity database searching

The power of in silico structure searching to achieve data driven decision making with confidence

In this blog, we explore the value of chemical structure search functionality in Vitic. Structure searching directs our members toward toxicity insights …

ICH Q3E - what the new guidelines mean for you

ICH Q3E – what the new E&L draft guideline means for you

The release of the ICH Q3E for public consultation marks a significant milestone for the pharmaceutical industry. It sets out a harmonised, …